Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CHMA

Chiasma (CHMA) Stock Price, News & Analysis

Chiasma logo

About Chiasma Stock (NASDAQ:CHMA)

Key Stats

Today's Range
$3.76
$3.76
50-Day Range
$3.76
$4.71
52-Week Range
$2.77
$5.74
Volume
147 shs
Average Volume
2.12 million shs
Market Capitalization
$217.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Receive CHMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

CHMA Stock News Headlines

Chiasma Craters on FDA Drug Rejection
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
MPM ASSET MANAGEMENT LLC Buys - GuruFocus.com
See More Headlines

CHMA Stock Analysis - Frequently Asked Questions

Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to analyst estimates of $1.80 million.

Chiasma (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
5/06/2021
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CHMA
Fax
N/A
Employees
85
Year Founded
N/A

Profitability

Net Income
$-74,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
$1.59 per share

Miscellaneous

Free Float
N/A
Market Cap
$217.68 million
Optionable
Not Optionable
Beta
1.28

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CHMA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners